Long-term Clinical Outcomes With Sunitinib for Patients With mRCC, Varying Characteristics

By Zachary Bessette - Last Updated: December 6, 2022

For patients with metastatic renal cell carcinoma (mRCC), durable complete response to sunitinib can be achieved irrespective of prognostic group, metastasis site, or histology type, according to new research published in Clinical Genitourinary Cancer.

Sunitinib, a tyrosine kinase inhibitor, was a standard treatment for mRCC until the introduction of immunotherapy. However, the long-term clinical outcomes and complete response in patients with mRCC treated with sunitinib are relatively unknown, and the characteristics of these patients could reveal unidentified associations with clinical variables.

Spanish researchers designed an observational retrospective study (ATILA) that analyzed the characteristics of patients with complete response to sunitinib to better understand associations with clinical variables. A total of 62 patients with mRCC who received first-line sunitinib and achieved a complete response from 2007 to 2018 in Spain were included in the study. Of those patients, 77.4% (n=48) received monotherapy sunitinib and 22.6% (n=14) received sunitinib combined with or followed by local treatment.

Researchers noted that the median age was 58.5 years, 79% of patients had clear cell histology, 90.3% had undergone previous nephrectomy, and 70.2% of patients had an intermediate International Metastatic RCC Database Consortium prognosis (while 23% and 7% had favorable and poor prognoses, respectively).

Additionally, the median time on sunitinib treatment was 28.2 months, and the median time to complete response was 10.9 months.

The median progression-free survival was not reached after a median follow-up of 8 years. The overall median duration of complete response was 64.1 months.

“A complete response to sunitinib could be achieved irrespective of prognostic group, metastasis site, or histology type,” the study authors concluded.